Key result
Aspirin and enalapril partially inhibited invasive pancreatic cancer in transgenic mice, occurring in 17.6% and 23.5% respectively, vs 60% in untreated controls.
Why the study?
Does aspirin and/or enalapril prevent progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer?
RCT (n=75)
Randomized
Does aspirin and/or enalapril prevent progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer?
Aspirin and enalapril demonstrated chemopreventive properties by delaying the progression of pancreatic intraepithelial neoplasia and partially inhibiting invasive pancreatic cancer formation in a transgenic mouse model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for chemoprevention in pancreatic neoplasia models; leaves open any human translation or practice change.
BACKGROUND AND AIMS: There are no chemopreventive strategies for pancreatic cancer or its precursor lesions, pancreatic intraepithelial neoplasia (PanINs). Recent evidence suggests that aspirin and inhibitors of angiotensin-I converting enzyme (ACE inhibitors) have potential chemopreventive properties. In this study, we used a genetically engineered mouse model of pancreatic cancer to evaluate the chemopreventive potential of these drugs. METHODS: Drug treatment was initiated at the age of 5 weeks. LsL-Kras(G12D); Pdx1-Cre or LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre transgenic mice were randomly assigned to receive either mock treatment, aspirin, enalapril, or a combination of both. After 3 and 5 months, animals were killed. The effect of aspirin and enalapril was evaluated by histopathological analyses, immunostaining, and real-time PCR. RESULTS: After 3 and 5 months of treatment, enalapril and aspirin were able to significantly delay progression of mPanINs in LsL-Kras(G12D); Pdx1-Cre mice. Furthermore, development of invasive pancreatic cancer in LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre transgenic mice was partially inhibited by enalapril and aspirin. Invasive pancreatic cancer was identified in 15 of 25 (60%) LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre untreated control mice, but in only three of 17 (17.6%, p=0.01) mice treated with aspirin, in four of 17 (23.5%, p=0.03) in mice treated with enalapril alone, and in five of 16 (31.2%, p=0.11) mice treated with a combination of both drugs. Using real-time PCR we found a significant downregulation of the target genes VEGF and RelA demonstrating our ability to achieve effective pharmacological levels of aspirin and enalapril during pancreatic cancer formation in vivo. CONCLUSION: Using a transgenic mouse model that imitates human pancreatic cancer, this study provides first evidence that aspirin and enalapril are effective chemopreventive agents by delaying the progression of PanINs and partially inhibiting the formation of murine pancreatic cancer. This study together supports the hypothesis that aspirin and ACE inhibitors might be a valid chemopreventive strategy.
No takes yet. Share an insight, caveat, or question.
Fendrich et al. (2009) conducted an RCT in Pancreatic cancer (n=75). Aspirin and/or enalapril vs. Mock treatment (untreated control) was evaluated on Development of invasive pancreatic cancer (p=0.01). Aspirin and enalapril partially inhibited invasive pancreatic cancer in transgenic mice, occurring in 17.6% and 23.5% respectively, vs 60% in untreated controls.
Synapse has enriched 10 related papers. Consider them for comparative context: